These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22584748)

  • 1. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.
    Veereman-Wauters G; de Ridder L; Veres G; Kolacek S; Fell J; Malmborg P; Koletzko S; Dias JA; Misak Z; Rahier JF; Escher JC;
    J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):830-7. PubMed ID: 22584748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of infectious complications in IBD.
    Rahier JF
    Dig Dis; 2012; 30(4):408-14. PubMed ID: 22796807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry.
    Lichtenstein GR; Feagan BG; Cohen RD; Salzberg BA; Diamond RH; Chen DM; Pritchard ML; Sandborn WJ
    Clin Gastroenterol Hepatol; 2006 May; 4(5):621-30. PubMed ID: 16678077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections.
    Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B
    Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
    Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease.
    Orlando A; Armuzzi A; Papi C; Annese V; Ardizzone S; Biancone L; Bortoli A; Castiglione F; D'Incà R; Gionchetti P; Kohn A; Poggioli G; Rizzello F; Vecchi M; Cottone M; ;
    Dig Liver Dis; 2011 Jan; 43(1):1-20. PubMed ID: 20843756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nested case-control study on risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Gong SS; Fan YH; Han QQ; Lv B; Xu Y
    World J Gastroenterol; 2019 May; 25(18):2240-2250. PubMed ID: 31143074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis.
    Viget N; Vernier-Massouille G; Salmon-Ceron D; Yazdanpanah Y; Colombel JF
    Gut; 2008 Apr; 57(4):549-58. PubMed ID: 18178610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone.
    Singh SM; Rau NV; Cohen LB; Harris H
    CMAJ; 2004 Oct; 171(9):1063-4. PubMed ID: 15505269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease.
    Epple HJ
    Dig Dis; 2009; 27(4):555-9. PubMed ID: 19897974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.
    Lichtenstein GR; Diamond RH; Wagner CL; Fasanmade AA; Olson AD; Marano CW; Johanns J; Lang Y; Sandborn WJ
    Aliment Pharmacol Ther; 2009 Aug; 30(3):210-26. PubMed ID: 19392858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab therapy in pediatric patients 7 years of age and younger.
    Kelsen JR; Grossman AB; Pauly-Hubbard H; Gupta K; Baldassano RN; Mamula P
    J Pediatr Gastroenterol Nutr; 2014 Dec; 59(6):758-62. PubMed ID: 25419596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined immunosuppression is more dangerous than monotherapy: what is fact and what is fiction?
    Schölmerich J
    Dig Dis; 2012; 30(4):404-7. PubMed ID: 22796806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.